KalVista Pharmaceuticals (NASDAQ:KALV) Sees Unusually-High Trading Volume

Shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) saw an uptick in trading volume on Thursday . 1,665,708 shares changed hands during mid-day trading, an increase of 107% from the previous session’s volume of 806,634 shares.The stock last traded at $12.09 and had previously closed at $11.07.

Analysts Set New Price Targets

A number of brokerages recently commented on KALV. Needham & Company LLC increased their price target on shares of KalVista Pharmaceuticals from $22.00 to $35.00 and gave the company a “buy” rating in a report on Tuesday, February 13th. HC Wainwright raised their target price on shares of KalVista Pharmaceuticals from $16.00 to $24.00 and gave the stock a “buy” rating in a research report on Wednesday, February 14th.

KalVista Pharmaceuticals Price Performance

The company has a market capitalization of $500.37 million, a PE ratio of -3.79 and a beta of 0.90. The company’s fifty day moving average is $13.57 and its 200-day moving average is $11.06.

Insider Buying and Selling at KalVista Pharmaceuticals

In other KalVista Pharmaceuticals news, major shareholder Venrock Healthcare Capital Par bought 6,013 shares of the firm’s stock in a transaction that occurred on Friday, December 29th. The stock was bought at an average cost of $12.49 per share, for a total transaction of $75,102.37. Following the completion of the transaction, the insider now directly owns 4,092,731 shares of the company’s stock, valued at approximately $51,118,210.19. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. In other KalVista Pharmaceuticals news, CEO Thomas Andrew Crockett sold 24,888 shares of KalVista Pharmaceuticals stock in a transaction on Tuesday, February 20th. The shares were sold at an average price of $14.11, for a total value of $351,169.68. Following the completion of the transaction, the chief executive officer now owns 211,203 shares of the company’s stock, valued at $2,980,074.33. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, major shareholder Venrock Healthcare Capital Par acquired 6,013 shares of the business’s stock in a transaction on Friday, December 29th. The stock was purchased at an average cost of $12.49 per share, with a total value of $75,102.37. Following the acquisition, the insider now directly owns 4,092,731 shares of the company’s stock, valued at approximately $51,118,210.19. The disclosure for this purchase can be found here. Over the last three months, insiders bought 407,008 shares of company stock worth $5,309,358 and sold 115,878 shares worth $1,590,471. 12.30% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Point72 Hong Kong Ltd purchased a new stake in KalVista Pharmaceuticals during the 2nd quarter valued at about $26,000. Quantbot Technologies LP purchased a new stake in KalVista Pharmaceuticals during the 3rd quarter valued at about $31,000. Royal Bank of Canada grew its stake in KalVista Pharmaceuticals by 225.7% during the 2nd quarter. Royal Bank of Canada now owns 4,492 shares of the specialty pharmaceutical company’s stock valued at $40,000 after acquiring an additional 3,113 shares in the last quarter. Tower Research Capital LLC TRC grew its stake in KalVista Pharmaceuticals by 28.3% during the 4th quarter. Tower Research Capital LLC TRC now owns 3,482 shares of the specialty pharmaceutical company’s stock valued at $43,000 after acquiring an additional 768 shares in the last quarter. Finally, Barclays PLC grew its stake in KalVista Pharmaceuticals by 148.1% during the 4th quarter. Barclays PLC now owns 6,572 shares of the specialty pharmaceutical company’s stock valued at $45,000 after acquiring an additional 3,923 shares in the last quarter.

KalVista Pharmaceuticals Company Profile

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of small molecule protease inhibitors for diseases with unmet needs in the United States. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors.